10-Q: Ardent Health Reports Q3 Loss Amid Revenue Adjustment, Liability Hike

Ardent Health, Inc. reported a net loss of $23.48 million for Q3 2025, impacted by a $42.6 million revenue accounting estimate change and a $47.2 million increase in professional liability reserves.

Summary

• Net loss attributable to Ardent Health, Inc. was $23.48 million for the three months ended September 30, 2025, a significant decline from net income of $26.32 million in the prior year period.
• Net income attributable to Ardent Health, Inc. for the nine months ended September 30, 2025, decreased to $90.86 million from $96.14 million in the prior year period.
• Total revenue increased by 8.8% to $1.58 billion for the three months ended September 30, 2025, and by 8.2% to $4.72 billion for the nine months ended September 30, 2025.
• Q3 2025 revenue was negatively impacted by a $42.6 million reduction due to a change in accounting estimate related to the collectability of accounts receivable.
• Professional liability reserves increased by $47.2 million in Q3 2025, primarily due to adverse claim developments in the New Mexico market arising from a single provider employed between 2019 and 2022.
• Adjusted EBITDA for Q3 2025 was $143.02 million, up from $97.76 million in Q3 2024, and for the nine months ended September 30, 2025, was $411.09 million, up from $315.88 million.
• Net patient service revenue per adjusted admission increased by 5.8% for Q3 2025 and 5.7% for the nine months ended September 30, 2025.
• Admissions grew by 5.8% in Q3 2025 and 6.7% for the nine months ended September 30, 2025.
• The company refinanced its Term Loan B Facility on September 18, 2025, reducing the applicable interest rate by 50 basis points and extending the maturity date to September 18, 2032.
• Received $21.5 million in business insurance recovery proceeds related to the November 2023 cybersecurity incident during the nine months ended September 30, 2025.
• Acquired certain assets and operations of 18 urgent care clinics in New Mexico and Oklahoma on January 1, 2025, for a combined purchase price of $27.5 million.

Sentiment

Score: 4

Explanation: While revenue and Adjusted EBITDA showed growth, the significant net loss in Q3, driven by a large accounting adjustment and a substantial increase in professional liability reserves, indicates underlying operational and financial challenges. Regulatory changes from the OBBBA also present future headwinds. The debt refinancing is a positive, but the overall picture is mixed with notable negatives.

Positives

• Total revenue increased by 8.8% to $1.58 billion in Q3 2025 and by 8.2% to $4.72 billion for the nine months ended September 30, 2025.
• Adjusted EBITDA significantly increased to $143.02 million in Q3 2025 (from $97.76 million in Q3 2024) and to $411.09 million for the nine months (from $315.88 million).
• Net patient service revenue per adjusted admission increased by 5.8% in Q3 2025 and 5.7% for the nine months, driven by supplemental program revenue and reimbursement rates.
• Admissions grew by 5.8% in Q3 2025 and 6.7% for the nine months.
• Successful refinancing of the Term Loan B Facility on September 18, 2025, reduced the interest rate by 50 basis points and extended maturity to September 18, 2032.
• Received $21.5 million in business insurance recovery proceeds related to the November 2023 cybersecurity incident during the nine months ended September 30, 2025.
• Acquisition of 18 urgent care clinics in New Mexico and Oklahoma expands the company's market presence.
• Improvements in staffing efficiency and productivity contributed to a decrease in salaries and benefits as a percentage of total revenue (when adjusted for the accounting estimate change).
• Net leverage ratio of 1.0x and lease-adjusted net leverage ratio of 2.5x as of September 30, 2025, indicate manageable debt levels.

Negatives

• Net loss attributable to Ardent Health, Inc. of $23.48 million in Q3 2025, a significant decline from net income of $26.32 million in Q3 2024.
• A $42.6 million reduction in Q3 2025 revenue due to a change in accounting estimate for accounts receivable collectability.
• A $47.2 million increase in professional liability reserves in Q3 2025, primarily due to adverse claim developments in the New Mexico market from a single provider.
• Net income attributable to Ardent Health, Inc. for the nine months ended September 30, 2025, decreased to $90.86 million from $96.14 million in the prior year period.
• Total operating expenses increased by $186.2 million in Q3 2025, and 4.0% as a percentage of total revenue.
• Diluted EPS decreased to $(0.17) in Q3 2025 from $0.19 in Q3 2024.
• Diluted EPS for the nine months ended September 30, 2025, decreased to $0.64 from $0.74 in the prior year period.
• Other comprehensive loss, net of income taxes, was $(2.24) million for Q3 2025 and $(12.37) million for the nine months ended September 30, 2025.

Risks

• Possible reductions or other changes in Medicare, Medicaid, and other state programs, including supplemental payment programs, could adversely affect revenues and business.
• Reduction in reimbursement rates paid by commercial payors, increased reimbursement denials or payment delays, or inability to retain and negotiate favorable contracts with private third-party payors.
• Effects of changes in healthcare policy or legislation, including the One Big Beautiful Bill Act (OBBBA), which may reduce federal Medicaid expenditures, tighten eligibility, and cap payment rates.
• Security threats, catastrophic events, and other disruptions affecting information technology and related systems, as experienced with the November 2023 Cybersecurity Incident.
• The highly competitive nature of the healthcare industry and continued industry trends towards clinical transparency and value-based purchasing may impact competitive position.
• Inability to recruit and retain quality physicians and medical support personnel, as well as increasing costs to contract with hospital-based physicians.
• Changes to physician utilization practices and treatment methodologies and other factors outside the company's control that impact demand for medical services.
• Potential for future deficit reduction legislation, including sequestration spending reductions, which could result in Medicare reimbursement cuts of up to 4% in early 2026.
• Inability to successfully complete acquisitions or strategic joint ventures or inability to realize all of the anticipated benefits.
• Liabilities due to professional liability and other claims brought against hospitals, physician practices, or other operations, as evidenced by the $47.2 million increase in reserves in New Mexico.
• Exposure to certain risks and uncertainties by the joint ventures through which a significant portion of operations are conducted.
• Failure to obtain drugs and medical supplies at favorable prices or sufficient volumes.
• Operational, legal, and financial risks associated with outsourcing functions to third parties.
• Heavy concentration of facilities in Texas and Oklahoma makes the company sensitive to regulatory, economic, and competitive conditions in those states.
• Negative impact of severe weather, climate change, and other factors beyond control, which could restrict patient access or cause facility closures.
• Risks related to the Master Lease with Ventas and its restrictions and limitations on the business.
• The impact of significant indebtedness and the ability to refinance such indebtedness on acceptable terms.
• Failure to comply with complex laws and regulations applicable to the healthcare industry or to adjust operations in response to changing laws and regulations.
• The impact of governmental claims or investigations, payor audits, and litigation.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws, regulations, standards, and other requirements.
• The impact of a deterioration of public health conditions associated with a future pandemic, epidemic, or outbreak of infectious disease.
• Inability to or delay in building, acquiring, selling, renovating, or expanding healthcare facilities.
• Failure to comply with federal and state laws relating to Medicare and Medicaid enrollment, permit, licensing, and accreditation requirements.
• Risks related to the company's efforts to use technology, including artificial intelligence and machine learning, to drive efficiencies.
• Status as a controlled company and potential conflicts of interest between the controlling stockholder and other common stock holders.

Future Outlook

The recently enacted One Big Beautiful Bill Act (OBBBA) is expected to impact financial performance by potentially reducing federal Medicaid expenditures, tightening Medicaid eligibility requirements, and capping payment rates for certain services. The OBBBA also includes tax provisions, such as the return to the EBITDA formula for business interest expense limitation and the allowance of 100% bonus depreciation, which are expected to reduce current tax liability but not materially impact current year tax expense. Ongoing budgetary uncertainties and efforts to reduce the federal deficit may lead to further payment reductions in both Medicaid and Medicare programs, with potential Medicare cuts of up to 4% in early 2026 due to sequestration. Additionally, the OBBBA is expected to decrease the number of individuals obtaining health insurance from Affordable Care Act (ACA) marketplace exchanges by ending automatic renewals and eliminating federal enhanced subsidies.

Management Comments

• Our operations are dependent on the efforts, abilities and experience of our management and medical support personnel, such as nurses, pharmacists and lab technicians, as well as our physicians.
• We compete with other healthcare providers in recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our hospitals and other facilities, including nurses and other non-physician healthcare professionals.
• Management believes the Company was in compliance with all financial covenants as of September 30, 2025.
• Management believes that, as of September 30, 2025, the Company maintained more than the minimum amount of availability under the senior secured asset-based revolving credit facility and, therefore, the minimum fixed charge ratio described herein was not applicable.
• Management considers the impact of recent claim developments, actuarial inputs, advice of legal counsel, and other information pertinent to the matter to accrue an estimate for contingent liabilities when losses are both probable and reasonably estimable.
• Apart from ongoing litigation associated with unresolved professional liability claims as described above, management does not believe that the Company is party to any proceeding that, either individually or in the aggregate, could have a material adverse effect on its business, financial condition, results of operations or liquidity.
• We currently believe we have adequate liquidity to fund operations during the near term through the generation of operating cash flows, cash on hand and access to our ABL Facilities.

Industry Context

The healthcare industry continues to face a growing focus on healthcare spending by consumers, employers, and insurers, driving demand for lower-cost care solutions. There is an ongoing shift in patient volumes from inpatient to outpatient settings, fueled by technological advancements and a preference for more convenient, affordable, and accessible care. The growing aged population necessitates greater chronic disease management and higher-acuity treatment. Industry consolidation among providers and insurers persists. Regulatory uncertainty, particularly from changes in federal or state healthcare laws like the No Surprises Act and the recently enacted OBBBA, significantly impacts reimbursement rates and operational practices. Labor shortages and inflationary wage pressures remain significant operating issues across the healthcare sector.

Corporate Governance

Legal Proceedings

• An increase in professional liability reserves of $47.2 million as of September 30, 2025, due to adverse claim developments in the New Mexico market, primarily from a single provider employed between 2019 and 2022.
• The consolidated class action litigation (Hodge v. AHS Management Company, Inc.) related to the November 2023 ransomware cybersecurity incident was settled, with preliminary approval on October 9, 2024, and court-ordered implementation of the settlement following an August 1, 2025, hearing.
• The company has outstanding federal income tax refund claims for the 2016 and 2018 tax years totaling $10.0 million, which are subject to ongoing Joint Committee on Taxation reviews and a statute waiver through December 31, 2026.
• The company's tax years from 2021 through 2024 remain open to examination by federal and state taxing authorities.

Related Party Transactions

• The company leases 10 of its hospitals and certain medical office buildings from Ventas (a related party) under the Ventas Master Lease and other lease agreements. Rent expense was $38.1 million for Q3 2025 and $114.0 million for the nine months ended September 30, 2025.
• Ventas beneficially owned approximately 6.5% of the company's outstanding common stock as of September 30, 2025.

Stakeholder Impact

• Shareholders experienced a negative impact on net income and EPS due to the accounting estimate change and increased liability reserves, with potential future impacts from regulatory changes (OBBBA) and Medicare cuts. Positives include debt refinancing and urgent care acquisitions.
• Employees face continued dependence on recruiting and retaining qualified personnel, with ongoing labor shortages and inflationary wage pressures. Restructuring costs included severance related to workforce reductions.
• Patients/Customers continue to receive care through the company's network. A class action settlement was reached for individuals affected by the cybersecurity incident. Potential impacts on access and cost of care may arise from OBBBA changes to Medicaid eligibility and ACA subsidies.
• Creditors benefit from improved debt terms and extended maturity due to the Term Loan B Facility refinancing. The company reported compliance with financial covenants, including a net leverage ratio of 1.0x and a lease-adjusted net leverage ratio of 2.5x.
• Suppliers may continue to pass along rising costs to the company due to inflationary pressures.

Next Steps

• Finalize the fair values of assets and liabilities related to the urgent care clinic acquisitions.
• Implement the agreed-upon settlement for the consolidated class action litigation related to the Cybersecurity Incident.
• Monitor and adapt to the implementation of the One Big Beautiful Bill Act (OBBBA) provisions, including potential Medicaid expenditure reductions, eligibility changes, and payment rate caps.
• Prepare for potential Medicare reimbursement cuts of up to 4% in early 2026 due to sequestration.
• Evaluate the impact of new accounting standards ASU 2023-09 (Income Taxes), ASU 2024-03 (Disaggregation of Income Statement Expenses), and ASU 2025-06 (Internal-Use Software) on disclosures and financial statements.
• Make quarterly principal payments on the refinanced Term Loan B Facility starting December 31, 2025.

Key Dates

Recommendation

While Ardent Health, Inc. demonstrated revenue growth and an increase in Adjusted EBITDA, the significant net loss in Q3 2025, driven by a substantial accounting adjustment and a large increase in professional liability reserves, raises concerns about underlying profitability and risk management. The successful debt refinancing is a positive, but the evolving regulatory landscape, particularly with the One Big Beautiful Bill Act (OBBBA) and potential Medicare cuts, presents considerable future uncertainty. The stock is likely to experience volatility due to these mixed signals. A 'Hold' recommendation is appropriate as investors should monitor how the company navigates these challenges and integrates its recent acquisitions before making a more definitive move.

Keywords

Healthcare services, Hospital operations, Acute care, SEC filing, 10-Q, Financial results, Revenue, Net loss, Adjusted EBITDA, Debt refinancing, Professional liability, Urgent care, Acquisitions, Medicaid, Medicare, OBBBA, Cybersecurity, New Mexico, Texas, Oklahoma, New Jersey, Ventas, Healthcare policy, Regulatory risk